Research programme: CAR-T cell therapies - QLXB
Latest Information Update: 30 Aug 2023
At a glance
- Originator Shandong Qilu Cell Therapy Engineering Technology
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 14 Jun 2023 Early research in Unspecified in China (Parenteral) (Shandong Qilu Cell Therapy Engineering Technology pipeline, June 2023)